<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01583374</url>
  </required_header>
  <id_info>
    <org_study_id>CC-10004-AS-001</org_study_id>
    <secondary_id>2011-001555-37</secondary_id>
    <nct_id>NCT01583374</nct_id>
  </id_info>
  <brief_title>Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis</brief_title>
  <acronym>POSTURE</acronym>
  <official_title>A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Apremilast is a new, orally available, small molecule drug that specifically inhibits
      phosphodiesterase 4 (PDE4), an enzyme that modulates inflammatory cytokines. This clinical
      study tests whether apremilast can improve the signs and symptoms of ankylosing spondylitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were randomized in a 1:1:1 ratio to placebo, apremilast 20 mg BID and apremilast 30
      mg BID. The duration of the study was approximately 5 years. The double blind period (when
      patients nor the physician knew whether placebo or apremilast was taken) was 24 weeks. At
      Week 16, participants who did not have either a ≥ 20% improvement or a ≥ 1 unit improvement
      from baseline in at least two of the four SpondyloArthritis international Society (ASAS)
      domains were entered in &quot;early escape&quot; from their current treatment in a double-blinded
      manner. However, such participants were permitted to continue in the study. At Week 24,
      participants may have entered a long-term extension phase for up to an additional 4.5 years
      (236 weeks). At &quot;second escape&quot; (at Week 24), apremilast 20 mg BID treated participants
      transitioned to receive double-blinded apremilast 30 mg BID and remained on double-blinded
      apremilast 30 mg BID because they continued to improve with a longer duration of treatment.
      After Week 24 and during the early portion of the long-term extension through Week 52, all
      participants continued on either double-blinded apremilast 20 mg BID or 30 mg BID treatment.
      After all participants had completed Week 52 or had terminated early from the study and the
      52-week data base was locked, apremilast 20 mg BID or 30 mg BID treatment was provided.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2, 2012</start_date>
  <completion_date type="Actual">October 25, 2018</completion_date>
  <primary_completion_date type="Actual">February 24, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <description>ASAS 20 was defined as achieving an improvement from baseline of ≥ 20% and ≥ 1 unit in at least 3 of 4 ASAS domains on a scale of 0 to 10 units and no worsening from baseline of ≥ 20% and ≥ 1 unit in the remaining ASAS domain on a scale of 0 to 10 units. The 4 ASAS domains are:
Patient Global Assessment of Disease (0 - 10 unit Numerical Rating Scale [NRS]); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = not active and the right-hand box = very active
Total Back Pain (0 to 10 unit NRS); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = &quot;no pain&quot; and the right-hand box = &quot;most severe pain&quot;
Function (Bath AS Functional Index [BASFI] NRS 0 - 10 unit); participant provides a self-administered survey of 10 questions assessing for degree of mobility and functional ability
Inflammation domain is determined by the mean of 2 Bath AS Disease Activity Index NRS Questions #5 and #6 for morning stiffness) (0 - 10 unit)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The BASFI is a composite score based on a self-administered survey of 10 questions using a 0 to 10 unit numerical rating scale (NRS) that assesses the degree of mobility and functional ability. The survey consists of 8 questions regarding function in AS and the last 2 reflect the ability to manage everyday life. The patient marks a box with an X on a 0 to 10 unit NRS for 10 questions; the left-hand box of 0 = easy; the right-hand box = impossible. The resulting 0 to 100 score is divided by 10 to give a final 0 to 10 BASFI score. The overall score is the mean of the 10 items and ranges from 0 to 10. A higher score correlates to reduced functional ability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The BASDAI is a composite score based on a participant self-administered survey of six questions measured using a 0 to 10 unit numerical rating scale (NRS) that assessed the participants' five major symptoms of AS: 1) fatigue; 2) spinal pain; 3) peripheral joint pain/swelling; 4) areas of localized tenderness; 5a) morning stiffness severity upon wakening; 5b) morning stiffness duration upon wakening. The participant was asked to mark the box with an X on a 0 to 10 unit NRS for each of the 6 questions. To give each of the five symptoms equal weighting, the mean of the two scores relating to morning stiffness was taken. The resulting 0 to 50 score was divided by 5 to give a final 0 to 10 BASDAI score. A BASDAI score of 4 or greater was considered to be indicative of active AS disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>ASAS 20 was defined as achieving an improvement from baseline of ≥ 20% and ≥ 1 unit in at least 3 of 4 ASAS domains on a scale of 0 to 10 units and no worsening from baseline of ≥ 20% and ≥ 1 unit in the remaining ASAS domain on a scale of 0 to 10 units. The 4 ASAS domains are:
Patient Global Assessment of Disease (0 - 10 unit Numerical Rating Scale [NRS]); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = not active and the right-hand box = very active
Total Back Pain (0 to 10 unit NRS); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = &quot;no pain&quot; and the right-hand box = &quot;most severe pain&quot;
Function (Bath AS Functional Index [BASFI] NRS 0 - 10 unit); participant provides a self-administered survey of 10 questions assessing for degree of mobility and functional ability
Inflammation domain is determined by the mean of 2 Bath AS Disease Activity Index NRS Questions #5 and #6 for morning stiffness) (0 - 10 unit)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The ASQoL is a validated disease specific patient reported outcomes instrument to assess the impact of ankylosing spondylitis on the quality of life of individuals with emphasis on the ability of the person to fulfill his or her needs. It consisted of 18 items requesting a yes (score=1) or no (score=0) response to questions related to the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. The summary score ranges 0-18 with higher scores indicating worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) was a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores (based on US general population with mean of 50 and standard deviation of 10) were used in analyses. Higher scores indicate a higher level of functioning. The PCS encompasses physical functioning, role-physical, and bodily pain, as well as general health and vitality. A positive change from baseline score indicates an improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The BASMI-Linear was designed to assess axial status (ie, cervical, dorsal and lumbar spine, hips, and pelvic soft tissue) and to define clinically significant changes in spinal movement. Five dimensions of movement (lateral lumbar flexion, tragus to wall, forward lumbar flexion, maximal intermalleolar distance, and cervical rotation) were measured and normalized on 0 to 10 unit NRS. The average of these scores was the total BASMI score, ranging from 0-10 with higher values indicating more severe limitation in spinal mobility.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260</measure>
    <time_frame>Baseline to Week 104 and 260</time_frame>
    <description>The Modified Stoke Ankylosing Spondylitis Spine Score is a scoring method used to determine the amount or degree of ankylosing spondylitis disease that is in the spine based on x-ray radiographs of the spine. The m-SASSS scores 0-3.
0 = No abnormality, 1 = Erosion, Sclerosis or Squaring, 2 = Syndesmophyte, 3 = Total bony Bridging at each Site. An increase in the m-SASSS indicated a worsening of AS disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase</measure>
    <time_frame>From Week 0 to Week 24; the median duration of exposure was 23.57 weeks for the placebo arm, 23.71 weeks for the apremilast 20 mg arm and 24.00 weeks for the apremilast 30 mg arm.</time_frame>
    <description>A TEAE was an adverse event (AE) with a start date on or after the date of the first dose of IP and no later than 28 days after the last dose of IP for participants who discontinued early. A serious AE = results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; or constitutes an important medical event. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = symptoms causing severe pain discomfort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period</measure>
    <time_frame>Week 0 to week 260; overall mean duration of exposure to apremilast 20 mg and 30 mg BID was 160.96 weeks</time_frame>
    <description>A TEAE was an adverse event (AE) with a start date on or after the date of the first dose of IP and no later than 28 days after the last dose of IP for participants who discontinued early. A serious AE = results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; or constitutes an important medical event. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = symptoms causing severe pain discomfort.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">490</enrollment>
  <condition>Ankylosing Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Apremilast 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apremilast 20 mg was taken orally twice a day (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apremilast 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apremilast 30 mg was taken orally twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identically matched placebo tablets were taken orally twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast tablet 20 mg</intervention_name>
    <description>Apremilast 20 mg was taken orally twice a day (BID)</description>
    <arm_group_label>Apremilast 20 mg</arm_group_label>
    <other_name>Otezla; CC-10004</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast tablet 30 mg BID</intervention_name>
    <description>Apremilast 30 mg was taken orally twice a day</description>
    <arm_group_label>Apremilast 30 mg</arm_group_label>
    <other_name>Otezla; CC-10004</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identically matched placebo tablets were taken orally twice a day during the placebo controlled phase.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have a documented diagnosis of ankylosing spondylitis as defined by low back pain
             and stiffness, which improves with exercise, but is not relieved by rest for more than
             3 months prior to screening. At the completion of screening procedures, a documented
             diagnosis of definite active AS, as defined by the modified New York criteria (1984)
             whereby both criteria, at least 1 radiographic criterion and at least 1 clinical
             criterion, must be met

          -  Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is ≥ 4

          -  Total back pain is ≥ 4

          -  On stable dose of AS medication (or lack of medication) prior to randomization and
             through week 24

        Exclusion Criteria:

        - Prior treatment with a Tumor Necrosis Factor (TNF) blocker and any biologic treatment for
        AS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Valley Arthritis Center</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0943</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Medical Advances</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Arthritis Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advent Clinical Research Centers, Inc</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burnette &amp; Silverfield, MDS PLC</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alastair Kennedy, MD Research</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Medical Faculty Foundation</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klein and Associates MD, PA</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klein and Associates MD, PA</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Study Group</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Paul Rheumatology, PA</name>
      <address>
        <city>Eagan</city>
        <state>Minnesota</state>
        <zip>55121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Systems</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>STAT Research, Inc.</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramesh C Gupta MD</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Regional Clinic</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Hospitals and Clinics</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology and Immunotherapy Center</name>
      <address>
        <city>Franklin</city>
        <state>Wisconsin</state>
        <zip>53132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Research</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emeritus Research</name>
      <address>
        <city>Camberwell</city>
        <state>Victoria</state>
        <zip>3124</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Joint Care</name>
      <address>
        <city>Maroochydore</city>
        <zip>4558</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <zip>6849</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville South</city>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Wien-Hietzing</name>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic and Consulting Center Sv. Pantaleymon</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Multiprofile Transport Hospital Tzar Boris III</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>17 Diagnostic and Consulting Centre</name>
      <address>
        <city>Sofia</city>
        <zip>1505</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy - MHAT</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Consulting Center N4</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic: University of Calgary Heritage Medical Research Clinic (HMRC),Teaching Research and Wellness (TRW)</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nexus Clinical Research</name>
      <address>
        <city>St John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 5EB</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cividino Medicine Professional Corporation</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 2B6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. William G. Bensen Medicine Professional Corporation</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Credit Valley Professional Building</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis Program Research Group Inc.</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 3R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Research Associates</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H1A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 258</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Saint-Louis</name>
      <address>
        <city>Saint-Louis</city>
        <state>Quebec</state>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologie s.r.o.</name>
      <address>
        <city>Brno</city>
        <zip>638 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARTMEDI UPD s.r.o.</name>
      <address>
        <city>Hostivice</city>
        <zip>253 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARTHROMED s.r.o.</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medifin a.s, Šustova</name>
      <address>
        <city>Praha 11</city>
        <zip>148 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicka Ambulance</name>
      <address>
        <city>Praha 4</city>
        <zip>140 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Thomayerova nemocnice s poliklinikou - Klinicko-farmakologicka jednotka</name>
      <address>
        <city>Praha</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicka Ambulance</name>
      <address>
        <city>Sokolov</city>
        <zip>356 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PV-Medical s.r.o.</name>
      <address>
        <city>Zlin</city>
        <zip>760 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innomedica Medical and Research Centre</name>
      <address>
        <city>Tallinn</city>
        <zip>10117</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>11412</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Centre Ltd</name>
      <address>
        <city>Tartu</city>
        <zip>50106</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Ambroise-Pare</name>
      <address>
        <city>Boulogne</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPROS - CHR ORLEANS - Hôpital de la Source</name>
      <address>
        <city>Orléans Cedex 2</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié- Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum fur innovative Diagnostik und Therapie Rheumatologie Immunologie GmbH</name>
      <address>
        <city>Frankfurt</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schön Klink Hamburg-Eilbek</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Ruhrgebiet</name>
      <address>
        <city>Herne</city>
        <zip>44649</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qualiclinic kft</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Magyarország Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pest Megyei Flor Ferenc Korhaz</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veszprem Megyei Csolnoky Ferenc Korhaz-Rendelointezet</name>
      <address>
        <city>Veszprém</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk</name>
      <address>
        <city>Bialystok</city>
        <zip>15-099</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Osteo-Medic sc A. Racewicz J. Supronik</name>
      <address>
        <city>Bialystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus SCM Sp. z o.o.</name>
      <address>
        <city>Gdynia</city>
        <zip>81-537</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zespol Poradni Specjalistycznych</name>
      <address>
        <city>Lublin</city>
        <zip>20-582</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prywatna Praktyka Lekarska Pawel Hrycaj</name>
      <address>
        <city>Poznan</city>
        <zip>61-397</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ NASZ LEKARZ Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus SCM Sp. z o.o.</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cristei R. Rodica - Private Medical Practice</name>
      <address>
        <city>Braila</city>
        <zip>810019</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sf. Maria Clinical Hospital</name>
      <address>
        <city>Bucharest</city>
        <zip>011172</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency County Clinical Hospital</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sf Apostol Andrei Emergency Clinical County Hospital</name>
      <address>
        <city>Galati</city>
        <zip>800578</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RK Medcenter SRL</name>
      <address>
        <city>Iasi</city>
        <zip>700127</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sverdlovsk Regional Clinical Hospital 1</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Medical Complex Vashe Zdorovie</name>
      <address>
        <city>Kazan</city>
        <zip>420103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kemerovo Regional Clinical Hospital</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budget Institution &quot;Rheumatology Research Institute RAMS&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizhniy Novgorod State Medical Academy of Roszdrav</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Departmental Hospital at Smolensk Station RZhD JSC</name>
      <address>
        <city>Smolensk</city>
        <zip>214025</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital</name>
      <address>
        <city>Vladimir</city>
        <zip>600023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narodny ustav reumatickych chorob</name>
      <address>
        <city>Piestany</city>
        <zip>921 12</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUDr. Zuzana Cizmarikova, s.r.o., Reumatologick ambulancia</name>
      <address>
        <city>Poprad</city>
        <zip>058 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario a Coruna</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <zip>14001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitaria Parc Tauli de Sabadell</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago de Compostela Travesía de la Choupana s/n</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skånes Universitetssjukhus- Malmö</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnsley Hospital</name>
      <address>
        <city>Barnsley</city>
        <zip>S75 2EP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal National Hospital for Rheumatic Diseases</name>
      <address>
        <city>Bath</city>
        <zip>BA1 1RL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chapel Allerton Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS7 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuffield Orthopaedic Centre</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <reference>
    <citation>Gladman DD, Kavanaugh A, Gómez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, Guerette B, Delev N, Teng L, Edwards CJ, Birbara CA, Mease PJ. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. RMD Open. 2018 Jun 27;4(1):e000669. doi: 10.1136/rmdopen-2018-000669. eCollection 2018.</citation>
    <PMID>30018799</PMID>
  </reference>
  <reference>
    <citation>Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, Teng L, Paris M, Mease PJ. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. Arthritis Res Ther. 2019 May 10;21(1):118. doi: 10.1186/s13075-019-1901-3.</citation>
    <PMID>31077258</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 20, 2012</study_first_submitted>
  <study_first_submitted_qc>April 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2012</study_first_posted>
  <results_first_submitted>February 24, 2015</results_first_submitted>
  <results_first_submitted_qc>March 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 17, 2015</results_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spondylitis</keyword>
  <keyword>spondyloarthritis</keyword>
  <keyword>Spondyloarthropathy</keyword>
  <keyword>Oral preparation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Apremilast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>http://www.amgen.com/datasharing</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study enrolled participants at 88 study sites and in 18 countries (Australia, Austria, Bulgaria, Czech Republic, Estonia, France, Germany, Hungary, the Netherlands, Poland, Romania, Russia, Slovakia, Spain, the United Kingdom, Canada, Sweden, and the United States [US]).</recruitment_details>
      <pre_assignment_details>Randomized participants were stratified by the following 2 parameters:
C-Reactive Protein (CRP) concentration (normal: ≤ 1.5 mg/dL or elevated: &gt; 1.5 mg/dL) at screening;
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score &lt; 6.0 or BASDAI score ≥ 6.0 at baseline.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants initially randomized to receive placebo tablets BID in the 24-week placebo-controlled phase.</description>
        </group>
        <group group_id="P2">
          <title>Apremilast 20 mg</title>
          <description>Participants initially randomized to 20 mg apremilast tablets BID in the 24-week placebo-controlled phase continued to receive 20 mg apremilast tablets BID for up to 4.5 years in the long-term extension phase.</description>
        </group>
        <group group_id="P3">
          <title>Apremilast 30 mg</title>
          <description>Participants initially randomized to 30 mg apremilast tablets BID in the 24-week placebo-controlled phase, continued to receive 30 mg apremilast tablets BID for up to 4.5 years in the long-term extension phase.</description>
        </group>
        <group group_id="P4">
          <title>Placebo / Apremilast 30 mg Early Escape (EE)</title>
          <description>Participants initially randomized to receive placebo tablets BID who did not have at least 20% improvement or ≥ 1 unit improvement from baseline in 2 out of 4 of the Assessment of SpondyloArthritis International Society (ASAS) domains at Week 16 were transitioned to 30 mg apremilast tablets BID and continued to receive 30 mg apremilast tablets BID for up to 4.5 years in the long-term extension phase.</description>
        </group>
        <group group_id="P5">
          <title>Placebo/Apremilast 30 mg Crossover (XO)</title>
          <description>Participants initially randomized to placebo tablets BID in the 24-week placebo controlled phase were transitioned to 30 mg apremilast tablets BID at Week 24 and continued to receive 30 mg apremilast tablets BID for up to 4.5 years in the long-term extension phase.</description>
        </group>
        <group group_id="P6">
          <title>Apremilast 30 mg /Apremilast 30 mg EE</title>
          <description>Participants initially randomized to 30 mg apremilast tablets BID in the 24-week placebo-controlled phase who did not have at least 20% improvement or a ≥ 1-unit improvement from baseline in 2 of the 4 ASAS domains at Week 16 continued to receive 30 mg apremilast tablets BID for up to 4.5 years in the long-term extension phase.</description>
        </group>
        <group group_id="P7">
          <title>Apremilast 20 mg /Apremilast 30 mg EE</title>
          <description>Participants initially randomized to 20 mg apremilast tablets BID who did not have at least 20% improvement or ≥ 1 unit improvement from baseline in 2 out of 4 of the ASAS domains at Week 16 were transitioned to 30 mg apremilast tablets BID and continued to receive 30 mg apremilast tablets BID for up to 4.5 years in the long-term extension phase.</description>
        </group>
        <group group_id="P8">
          <title>Apremilast 30 mg /Apremilast 30 mg Second Escape (SE)</title>
          <description>Participants initially randomized to 30 mg apremilast tablets BID who did not have at least 20% improvement or ≥ 1 unit improvement from baseline in 2 out of 4 of the ASAS domains from baseline at Week 24 continued to receive 30 mg apremilast tablets BID (second escape) for up to 4.5 years in the long-term extension phase.</description>
        </group>
        <group group_id="P9">
          <title>Apremilast 20 mg/Apremilast 30 mg SE</title>
          <description>Participants initially randomized to 20 mg apremilast tablets BID who did not have at least 20% improvement or ≥ 1 unit improvement from baseline in 2 out of 4 of the ASAS domains at Week 24 were transitioned to 30 mg apremilast tablets BID (second escape) and continued to receive 30 mg apremilast tablets BID for up to 4.5 years in the long-term extension phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Placebo-controlled Phase (Week 0-24)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="163"/>
                <participants group_id="P3" count="163"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="163"/>
                <participants group_id="P3" count="163"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Week 16</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="151"/>
                <participants group_id="P3" count="144"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Early Escape at Week 16</title>
              <participants_list>
                <participants group_id="P1" count="51">One participant who escaped early did not complete Week 24</participants>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="49">One participant who escaped early did not complete Week 24</participants>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="145">Completed = participants who completed the Placebo-controlled Phase</participants>
                <participants group_id="P2" count="147">Completed = participants who completed the Placebo-controlled Phase</participants>
                <participants group_id="P3" count="138">Completed = participants who completed the Placebo-controlled Phase</participants>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Phase (Weeks 24 to 52)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="65"/>
                <participants group_id="P4" count="47"/>
                <participants group_id="P5" count="91"/>
                <participants group_id="P6" count="48"/>
                <participants group_id="P7" count="48"/>
                <participants group_id="P8" count="25"/>
                <participants group_id="P9" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="61"/>
                <participants group_id="P4" count="41"/>
                <participants group_id="P5" count="85"/>
                <participants group_id="P6" count="43"/>
                <participants group_id="P7" count="43"/>
                <participants group_id="P8" count="22"/>
                <participants group_id="P9" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Long-Term Extension Phase Weeks 52-260</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="61"/>
                <participants group_id="P4" count="35"/>
                <participants group_id="P5" count="81"/>
                <participants group_id="P6" count="39"/>
                <participants group_id="P7" count="38"/>
                <participants group_id="P8" count="21"/>
                <participants group_id="P9" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="22"/>
                <participants group_id="P7" count="20"/>
                <participants group_id="P8" count="12"/>
                <participants group_id="P9" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="31"/>
                <participants group_id="P6" count="17"/>
                <participants group_id="P7" count="18"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncomplinace with Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The modified Intent to Treat (mITT) population included all participants who were randomized and received at least one dose of investigational product (IP); Five participants did not have a baseline SF-36 Physical Component Summary score.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants initially randomized to receive placebo tablets BID in the 24-week placebo-controlled phase.</description>
        </group>
        <group group_id="B2">
          <title>Apremilast 20 mg</title>
          <description>Participants initially randomized to 20 mg apremilast tablets BID in the 24-week placebo-controlled phase continued to receive 20 mg apremilast tablets BID for up to 4.5 years in the long-term extension phase.</description>
        </group>
        <group group_id="B3">
          <title>Apremilast 30 mg</title>
          <description>Participants initially randomized to 30 mg apremilast tablets BID in the 24-week placebo-controlled phase.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="164"/>
            <count group_id="B2" value="163"/>
            <count group_id="B3" value="163"/>
            <count group_id="B4" value="490"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="164"/>
                    <count group_id="B2" value="163"/>
                    <count group_id="B3" value="163"/>
                    <count group_id="B4" value="490"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.0" spread="12.89"/>
                    <measurement group_id="B2" value="45.2" spread="11.90"/>
                    <measurement group_id="B3" value="44.8" spread="11.75"/>
                    <measurement group_id="B4" value="44.7" spread="12.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="164"/>
                    <count group_id="B2" value="163"/>
                    <count group_id="B3" value="163"/>
                    <count group_id="B4" value="490"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="164"/>
                    <count group_id="B2" value="163"/>
                    <count group_id="B3" value="163"/>
                    <count group_id="B4" value="490"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="162"/>
                    <measurement group_id="B4" value="479"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="164"/>
                    <count group_id="B2" value="163"/>
                    <count group_id="B3" value="163"/>
                    <count group_id="B4" value="490"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="158"/>
                    <measurement group_id="B4" value="470"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Ankylosing Spondylitis (Lower Back Pain and Stiffness)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="164"/>
                    <count group_id="B2" value="163"/>
                    <count group_id="B3" value="163"/>
                    <count group_id="B4" value="490"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.40" spread="10.375"/>
                    <measurement group_id="B2" value="11.06" spread="11.302"/>
                    <measurement group_id="B3" value="10.32" spread="9.887"/>
                    <measurement group_id="B4" value="10.60" spread="10.521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Ankylosing Spondylitis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="164"/>
                    <count group_id="B2" value="163"/>
                    <count group_id="B3" value="163"/>
                    <count group_id="B4" value="490"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>≤ 2 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="129"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;2 to ≤ 5 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;5 to ≤ 10 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;10 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Bath Ankylosing Spondylitis Functional Index (BASFI) Score (0 - 10 NRS)</title>
          <description>The BASFI is a composite score based on a self-administered survey of 10 questions using a 0 to 10 unit numerical rating scale (NRS) that assesses the degree of mobility and functional ability. The survey consists of 8 questions regarding function in AS and the last 2 reflect the ability to manage everyday life. The patient marks a box with an X on a 0 to 10 unit NRS for 10 questions; the left-hand box of 0 = easy; the right-hand box = impossible. The resulting 0 to 100 score is divided by 10 to give a final 0 to 10 BASFI score. A higher score correlates to reduced functional ability.</description>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="164"/>
                    <count group_id="B2" value="163"/>
                    <count group_id="B3" value="163"/>
                    <count group_id="B4" value="490"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.76" spread="2.194"/>
                    <measurement group_id="B2" value="5.75" spread="2.061"/>
                    <measurement group_id="B3" value="5.65" spread="2.100"/>
                    <measurement group_id="B4" value="5.72" spread="2.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score (0 - 10 NRS)</title>
          <description>The BASDAI is a composite score based on a self-administered survey of 6 questions using a 0 to 10 unit NRS that assesses for 5 major symptoms of AS: fatigue; spinal pain; peripheral joint pain/swelling; areas of localized tenderness; morning stiffness severity upon wakening; morning stiffness duration upon wakening. To give each of the 5 symptoms equal weighting, the mean of the 2 scores relating to morning stiffness is taken. The resulting 0 to 50 score is divided by 5 to give a final 0 to 10 BASDAI score. A score of 4 or greater is considered to be indicative of active AS disease.</description>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="164"/>
                    <count group_id="B2" value="163"/>
                    <count group_id="B3" value="163"/>
                    <count group_id="B4" value="490"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.45" spread="1.319"/>
                    <measurement group_id="B2" value="6.46" spread="1.352"/>
                    <measurement group_id="B3" value="6.37" spread="1.357"/>
                    <measurement group_id="B4" value="6.42" spread="1.341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Bath Ankylosing Spondylitis Metrology Index (BASMI)-Linear Score (0 - 10 NRS)</title>
          <description>The BASMI-Linearis designed to assess axial status (ie, cervical, dorsal and lumbar spine, hips, and pelvic soft tissue) and to define clinically significant changes in spinal movement. 5 dimensions of movement (lateral lumbar flexion, tragus to wall, forward lumbar flexion, maximal intermalleolar distance, and cervical rotation) were measured and normalized on 0 to 10 unit NRS. The average of these scores is the total BASMI score, with a higher value indicating more severe limitation in spinal mobility.</description>
          <population>Three participants did not have baseline BASMI data.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="163"/>
                    <count group_id="B2" value="163"/>
                    <count group_id="B3" value="161"/>
                    <count group_id="B4" value="487"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.36" spread="1.608"/>
                    <measurement group_id="B2" value="4.63" spread="1.721"/>
                    <measurement group_id="B3" value="4.41" spread="1.700"/>
                    <measurement group_id="B4" value="4.47" spread="1.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score (0-18)</title>
          <description>The ASQoL is a validated disease specific patient reported outcomes instrument to assess the impact of ankylosing spondylitis on the QoL of individuals with emphasis on the ability of the person to fulfill his or her needs. It consisted of 18 items requesting a yes (score=1) or no (score=0) response to questions related to the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. The summary score ranges 0–18 with higher scores indicating worse quality of life.</description>
          <population>Four participants did not have a baseline ASQoL score.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="164"/>
                    <count group_id="B2" value="162"/>
                    <count group_id="B3" value="160"/>
                    <count group_id="B4" value="486"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.10" spread="4.639"/>
                    <measurement group_id="B2" value="8.38" spread="4.548"/>
                    <measurement group_id="B3" value="8.62" spread="4.935"/>
                    <measurement group_id="B4" value="8.50" spread="4.738"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Physical Component Summary Score of Medical Outcome Study Short Form 36-Item Survey</title>
          <description>The SF- 36 is a self-administered instrument that measures the impact of disease and consists of 36 questions in 8 domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Two overall summary scores can also be obtained—a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). The PCS and MCS scores are transformed to have a mean of 50 and standard deviation of 10, with higher scores indicating better health. Scale scores range from 0 to 100, with higher scores indicating better health.</description>
          <population>Five participants did not have a baseline SF-36 Physical Component Summary score.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="164"/>
                    <count group_id="B2" value="162"/>
                    <count group_id="B3" value="159"/>
                    <count group_id="B4" value="485"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.57" spread="7.821"/>
                    <measurement group_id="B2" value="31.89" spread="8.561"/>
                    <measurement group_id="B3" value="32.16" spread="8.846"/>
                    <measurement group_id="B4" value="32.20" spread="8.402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16</title>
        <description>ASAS 20 was defined as achieving an improvement from baseline of ≥ 20% and ≥ 1 unit in at least 3 of 4 ASAS domains on a scale of 0 to 10 units and no worsening from baseline of ≥ 20% and ≥ 1 unit in the remaining ASAS domain on a scale of 0 to 10 units. The 4 ASAS domains are:
Patient Global Assessment of Disease (0 - 10 unit Numerical Rating Scale [NRS]); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = not active and the right-hand box = very active
Total Back Pain (0 to 10 unit NRS); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = &quot;no pain&quot; and the right-hand box = &quot;most severe pain&quot;
Function (Bath AS Functional Index [BASFI] NRS 0 - 10 unit); participant provides a self-administered survey of 10 questions assessing for degree of mobility and functional ability
Inflammation domain is determined by the mean of 2 Bath AS Disease Activity Index NRS Questions #5 and #6 for morning stiffness) (0 - 10 unit)</description>
        <time_frame>Baseline and Week 16</time_frame>
        <population>The mITT population included participants who were randomized and received at least one dose of investigation product (IP). Participants who discontinued early due to lack of efficacy were counted as nonresponders, and last observation carried forward (LOCF) imputation was used for participants who discontinued for other reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants initially randomized to receive placebo tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
          <group group_id="O2">
            <title>Apremilast 20 mg</title>
            <description>Participants initially randomized to 20 mg apremilast tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
          <group group_id="O3">
            <title>Apremilast 30 mg</title>
            <description>Participants initially randomized to 30 mg apremilast tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16</title>
          <description>ASAS 20 was defined as achieving an improvement from baseline of ≥ 20% and ≥ 1 unit in at least 3 of 4 ASAS domains on a scale of 0 to 10 units and no worsening from baseline of ≥ 20% and ≥ 1 unit in the remaining ASAS domain on a scale of 0 to 10 units. The 4 ASAS domains are:
Patient Global Assessment of Disease (0 - 10 unit Numerical Rating Scale [NRS]); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = not active and the right-hand box = very active
Total Back Pain (0 to 10 unit NRS); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = &quot;no pain&quot; and the right-hand box = &quot;most severe pain&quot;
Function (Bath AS Functional Index [BASFI] NRS 0 - 10 unit); participant provides a self-administered survey of 10 questions assessing for degree of mobility and functional ability
Inflammation domain is determined by the mean of 2 Bath AS Disease Activity Index NRS Questions #5 and #6 for morning stiffness) (0 - 10 unit)</description>
          <population>The mITT population included participants who were randomized and received at least one dose of investigation product (IP). Participants who discontinued early due to lack of efficacy were counted as nonresponders, and last observation carried forward (LOCF) imputation was used for participants who discontinued for other reasons.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6"/>
                    <measurement group_id="O2" value="35.0"/>
                    <measurement group_id="O3" value="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.4383</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>2 sided p-value was based on CMH test adjusting for C-reactive protein (CRP) category and baseline BASDAI score category</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.3</ci_lower_limit>
            <ci_upper_limit>6.2</ci_upper_limit>
            <estimate_desc>Adjusted difference is the weighted average of the treatment differences across the 4 strata of screening CRP category and baseline BASDAI score category with the Cochran-Mantel-Haenszel (CMH) weights</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7427</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>2 sided p-value was based on CMH test adjusting for C-reactive protein (CRP) category and baseline BASDAI score category</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.0</ci_lower_limit>
            <ci_upper_limit>8.5</ci_upper_limit>
            <estimate_desc>Adjusted difference in proportions is the weighted average of the treatment differences across the 4 strata of screening CRP category and baseline BASDAI score category with the Cochran-Mantel-Haenszel weights.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24</title>
        <description>The BASFI is a composite score based on a self-administered survey of 10 questions using a 0 to 10 unit numerical rating scale (NRS) that assesses the degree of mobility and functional ability. The survey consists of 8 questions regarding function in AS and the last 2 reflect the ability to manage everyday life. The patient marks a box with an X on a 0 to 10 unit NRS for 10 questions; the left-hand box of 0 = easy; the right-hand box = impossible. The resulting 0 to 100 score is divided by 10 to give a final 0 to 10 BASFI score. The overall score is the mean of the 10 items and ranges from 0 to 10. A higher score correlates to reduced functional ability.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>The mITT population included those who were randomized and received at least one dose of IP. Missing data were imputed as baseline carried forward for participants who escaped early or discontinued early (prior to Week 24) due to lack of efficacy and LOCF for other early discontinuations</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants initially randomized to receive placebo tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
          <group group_id="O2">
            <title>Apremilast 20 mg</title>
            <description>Participants initially randomized to 20 mg apremilast tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
          <group group_id="O3">
            <title>Apremilast 30 mg</title>
            <description>Participants initially randomized to 30 mg apremilast tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24</title>
          <description>The BASFI is a composite score based on a self-administered survey of 10 questions using a 0 to 10 unit numerical rating scale (NRS) that assesses the degree of mobility and functional ability. The survey consists of 8 questions regarding function in AS and the last 2 reflect the ability to manage everyday life. The patient marks a box with an X on a 0 to 10 unit NRS for 10 questions; the left-hand box of 0 = easy; the right-hand box = impossible. The resulting 0 to 100 score is divided by 10 to give a final 0 to 10 BASFI score. The overall score is the mean of the 10 items and ranges from 0 to 10. A higher score correlates to reduced functional ability.</description>
          <population>The mITT population included those who were randomized and received at least one dose of IP. Missing data were imputed as baseline carried forward for participants who escaped early or discontinued early (prior to Week 24) due to lack of efficacy and LOCF for other early discontinuations</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.94" spread="0.136"/>
                    <measurement group_id="O2" value="-1.11" spread="0.137"/>
                    <measurement group_id="O3" value="-0.99" spread="0.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8032</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an ANCOVA model for change from baseline with treatment group, CRP and baseline BASDAI score as factors and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3624</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an ANCOVA model for change from baseline with treatment group, CRP and baseline BASDAI score as factors and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24</title>
        <description>The BASDAI is a composite score based on a participant self-administered survey of six questions measured using a 0 to 10 unit numerical rating scale (NRS) that assessed the participants' five major symptoms of AS: 1) fatigue; 2) spinal pain; 3) peripheral joint pain/swelling; 4) areas of localized tenderness; 5a) morning stiffness severity upon wakening; 5b) morning stiffness duration upon wakening. The participant was asked to mark the box with an X on a 0 to 10 unit NRS for each of the 6 questions. To give each of the five symptoms equal weighting, the mean of the two scores relating to morning stiffness was taken. The resulting 0 to 50 score was divided by 5 to give a final 0 to 10 BASDAI score. A BASDAI score of 4 or greater was considered to be indicative of active AS disease.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>The mITT population included those who were randomized and received at least one dose of IP. Missing data were imputed as baseline carried forward for participants who escaped early or discontinued early (prior to Week 24) due to lack of efficacy and LOCF for other early discontinuations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants initially randomized to receive placebo tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
          <group group_id="O2">
            <title>Apremilast 20 mg</title>
            <description>Participants initially randomized to 20 mg apremilast tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
          <group group_id="O3">
            <title>Apremilast 30 mg</title>
            <description>Participants initially randomized to 30 mg apremilast tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24</title>
          <description>The BASDAI is a composite score based on a participant self-administered survey of six questions measured using a 0 to 10 unit numerical rating scale (NRS) that assessed the participants' five major symptoms of AS: 1) fatigue; 2) spinal pain; 3) peripheral joint pain/swelling; 4) areas of localized tenderness; 5a) morning stiffness severity upon wakening; 5b) morning stiffness duration upon wakening. The participant was asked to mark the box with an X on a 0 to 10 unit NRS for each of the 6 questions. To give each of the five symptoms equal weighting, the mean of the two scores relating to morning stiffness was taken. The resulting 0 to 50 score was divided by 5 to give a final 0 to 10 BASDAI score. A BASDAI score of 4 or greater was considered to be indicative of active AS disease.</description>
          <population>The mITT population included those who were randomized and received at least one dose of IP. Missing data were imputed as baseline carried forward for participants who escaped early or discontinued early (prior to Week 24) due to lack of efficacy and LOCF for other early discontinuations.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.21" spread="0.136"/>
                    <measurement group_id="O2" value="-1.30" spread="0.136"/>
                    <measurement group_id="O3" value="-1.18" spread="0.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8618</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an ANCOVA model for change from baseline with treatment group, CRP and baseline BASDAI score as factors and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>0.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6262</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an ANCOVA model for change from baseline with treatment group, CRP and baseline BASDAI score as factors and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24</title>
        <description>ASAS 20 was defined as achieving an improvement from baseline of ≥ 20% and ≥ 1 unit in at least 3 of 4 ASAS domains on a scale of 0 to 10 units and no worsening from baseline of ≥ 20% and ≥ 1 unit in the remaining ASAS domain on a scale of 0 to 10 units. The 4 ASAS domains are:
Patient Global Assessment of Disease (0 - 10 unit Numerical Rating Scale [NRS]); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = not active and the right-hand box = very active
Total Back Pain (0 to 10 unit NRS); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = &quot;no pain&quot; and the right-hand box = &quot;most severe pain&quot;
Function (Bath AS Functional Index [BASFI] NRS 0 - 10 unit); participant provides a self-administered survey of 10 questions assessing for degree of mobility and functional ability
Inflammation domain is determined by the mean of 2 Bath AS Disease Activity Index NRS Questions #5 and #6 for morning stiffness) (0 - 10 unit)</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>The mITT population included participants who were randomized and received at least one dose of investigation product (IP). Participants who discontinued early due to lack of efficacy were counted as nonresponders, and last observation carried forward (LOCF) imputation was used for participants who discontinued for other reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants initially randomized to receive placebo tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
          <group group_id="O2">
            <title>Apremilast 20 mg</title>
            <description>Participants initially randomized to 20 mg apremilast tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
          <group group_id="O3">
            <title>Apremilast 30 mg</title>
            <description>Participants initially randomized to 30 mg apremilast tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24</title>
          <description>ASAS 20 was defined as achieving an improvement from baseline of ≥ 20% and ≥ 1 unit in at least 3 of 4 ASAS domains on a scale of 0 to 10 units and no worsening from baseline of ≥ 20% and ≥ 1 unit in the remaining ASAS domain on a scale of 0 to 10 units. The 4 ASAS domains are:
Patient Global Assessment of Disease (0 - 10 unit Numerical Rating Scale [NRS]); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = not active and the right-hand box = very active
Total Back Pain (0 to 10 unit NRS); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = &quot;no pain&quot; and the right-hand box = &quot;most severe pain&quot;
Function (Bath AS Functional Index [BASFI] NRS 0 - 10 unit); participant provides a self-administered survey of 10 questions assessing for degree of mobility and functional ability
Inflammation domain is determined by the mean of 2 Bath AS Disease Activity Index NRS Questions #5 and #6 for morning stiffness) (0 - 10 unit)</description>
          <population>The mITT population included participants who were randomized and received at least one dose of investigation product (IP). Participants who discontinued early due to lack of efficacy were counted as nonresponders, and last observation carried forward (LOCF) imputation was used for participants who discontinued for other reasons.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7"/>
                    <measurement group_id="O2" value="36.2"/>
                    <measurement group_id="O3" value="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6958</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>2 sided p-value was based on the CMH test adjusting for C-reactive protein (CRP) category and baseline BASDAI score category.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.1</ci_lower_limit>
            <ci_upper_limit>12.2</ci_upper_limit>
            <estimate_desc>Adjusted difference is the weighted average of the treatment differences across the 4 strata of screening CRP category and baseline BASDAI score category with the Cochran-Mantel-Haenszel weights.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4051</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>2 sided p-value was based on the CMH test adjusting for C-reactive protein (CRP) category and baseline BASDAI score category.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>4.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.8</ci_lower_limit>
            <ci_upper_limit>14.5</ci_upper_limit>
            <estimate_desc>Adjusted difference is the weighted average of the treatment differences across the 4 strata of screening CRP category and baseline BASDAI score category with the Cochran-Mantel-Haenszel weights.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24</title>
        <description>The ASQoL is a validated disease specific patient reported outcomes instrument to assess the impact of ankylosing spondylitis on the quality of life of individuals with emphasis on the ability of the person to fulfill his or her needs. It consisted of 18 items requesting a yes (score=1) or no (score=0) response to questions related to the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. The summary score ranges 0-18 with higher scores indicating worse quality of life.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>The mITT included those who were randomized and received at least one dose of IP. Missing data were imputed as baseline carried forward for participants who escaped early or discontinued early (prior to Week 24) due to lack of efficacy and LOCF for other early discontinuations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants initially randomized to receive placebo tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
          <group group_id="O2">
            <title>Apremilast 20 mg</title>
            <description>Participants initially randomized to 20 mg apremilast tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
          <group group_id="O3">
            <title>Apremilast 30 mg</title>
            <description>Participants initially randomized to 30 mg apremilast tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24</title>
          <description>The ASQoL is a validated disease specific patient reported outcomes instrument to assess the impact of ankylosing spondylitis on the quality of life of individuals with emphasis on the ability of the person to fulfill his or her needs. It consisted of 18 items requesting a yes (score=1) or no (score=0) response to questions related to the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. The summary score ranges 0-18 with higher scores indicating worse quality of life.</description>
          <population>The mITT included those who were randomized and received at least one dose of IP. Missing data were imputed as baseline carried forward for participants who escaped early or discontinued early (prior to Week 24) due to lack of efficacy and LOCF for other early discontinuations.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.77" spread="0.278"/>
                    <measurement group_id="O2" value="-1.50" spread="0.278"/>
                    <measurement group_id="O3" value="-1.52" spread="0.281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5126</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an ANCOVA model for change from baseline with treatment group, CRP and baseline BASDAI score as factors and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.49</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4624</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an ANCOVA model for change from baseline with treatment group, CRP and baseline BASDAI score as factors and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24</title>
        <description>The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) was a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores (based on US general population with mean of 50 and standard deviation of 10) were used in analyses. Higher scores indicate a higher level of functioning. The PCS encompasses physical functioning, role-physical, and bodily pain, as well as general health and vitality. A positive change from baseline score indicates an improvement</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>The mITT included those who were randomized and received at least one dose of IP. Missing data were imputed as baseline carried forward for participants who escaped early or discontinued early (prior to Week 24) due to lack of efficacy and LOCF for other early discontinuations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants initially randomized to receive placebo tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
          <group group_id="O2">
            <title>Apremilast 20 mg</title>
            <description>Participants initially randomized to 20 mg apremilast tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
          <group group_id="O3">
            <title>Apremilast 30 mg</title>
            <description>Participants initially randomized to 30 mg apremilast tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24</title>
          <description>The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) was a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores (based on US general population with mean of 50 and standard deviation of 10) were used in analyses. Higher scores indicate a higher level of functioning. The PCS encompasses physical functioning, role-physical, and bodily pain, as well as general health and vitality. A positive change from baseline score indicates an improvement</description>
          <population>The mITT included those who were randomized and received at least one dose of IP. Missing data were imputed as baseline carried forward for participants who escaped early or discontinued early (prior to Week 24) due to lack of efficacy and LOCF for other early discontinuations.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" spread="0.553"/>
                    <measurement group_id="O2" value="3.46" spread="0.551"/>
                    <measurement group_id="O3" value="3.79" spread="0.559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6997</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an ANCOVA model for change from baseline with treatment group, CRP and baseline BASDAI score as factors and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.18</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9587</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an ANCOVA model for change from baseline with treatment group, CRP and baseline BASDAI score as factors and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.50</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24</title>
        <description>The BASMI-Linear was designed to assess axial status (ie, cervical, dorsal and lumbar spine, hips, and pelvic soft tissue) and to define clinically significant changes in spinal movement. Five dimensions of movement (lateral lumbar flexion, tragus to wall, forward lumbar flexion, maximal intermalleolar distance, and cervical rotation) were measured and normalized on 0 to 10 unit NRS. The average of these scores was the total BASMI score, ranging from 0-10 with higher values indicating more severe limitation in spinal mobility.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>The mITT population included those who were randomized and received at least one dose of IP. Missing data were imputed as baseline carried forward for participants who escaped early or discontinued early (prior to Week 24) due to lack of efficacy and LOCF for other early discontinuations</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants initially randomized to receive placebo tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
          <group group_id="O2">
            <title>Apremilast 20 mg</title>
            <description>Participants initially randomized to 20 mg apremilast tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
          <group group_id="O3">
            <title>Apremilast 30 mg</title>
            <description>Participants initially randomized to 30 mg apremilast tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24</title>
          <description>The BASMI-Linear was designed to assess axial status (ie, cervical, dorsal and lumbar spine, hips, and pelvic soft tissue) and to define clinically significant changes in spinal movement. Five dimensions of movement (lateral lumbar flexion, tragus to wall, forward lumbar flexion, maximal intermalleolar distance, and cervical rotation) were measured and normalized on 0 to 10 unit NRS. The average of these scores was the total BASMI score, ranging from 0-10 with higher values indicating more severe limitation in spinal mobility.</description>
          <population>The mITT population included those who were randomized and received at least one dose of IP. Missing data were imputed as baseline carried forward for participants who escaped early or discontinued early (prior to Week 24) due to lack of efficacy and LOCF for other early discontinuations</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.042"/>
                    <measurement group_id="O2" value="-0.16" spread="0.043"/>
                    <measurement group_id="O3" value="-0.13" spread="0.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3307</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an ANCOVA model for change from baseline with treatment group, CRP and baseline BASDAI score as factors and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5938</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an ANCOVA model for change from baseline with treatment group, CRP and baseline BASDAI score as factors and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260</title>
        <description>The Modified Stoke Ankylosing Spondylitis Spine Score is a scoring method used to determine the amount or degree of ankylosing spondylitis disease that is in the spine based on x-ray radiographs of the spine. The m-SASSS scores 0-3.
0 = No abnormality, 1 = Erosion, Sclerosis or Squaring, 2 = Syndesmophyte, 3 = Total bony Bridging at each Site. An increase in the m-SASSS indicated a worsening of AS disease.</description>
        <time_frame>Baseline to Week 104 and 260</time_frame>
        <population>The radiograph subset analysis population included randomized participants who received at least one dose of IP and had at least a baseline radiograph available. Includes apremilast participants as treated who had a baseline and at least one post-baseline score. Missing scores were imputed using the LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Apremilast 20 mg</title>
            <description>Participants initially randomized to 20 mg apremilast tablets BID in the 24-week placebo-controlled phase, and continued to receive apremilast 20 mg or 30 mg during weeks 24 to 260.</description>
          </group>
          <group group_id="O2">
            <title>Apremilast 30 mg</title>
            <description>Participants initially randomized at Week 0 to 30 mg apremilast tablets BID in the 24-week placebo-controlled phase, and continued to receive apremilast 30 mg during weeks 24 to 260.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Apremilast 30 mg</title>
            <description>Participants who initially received placebo tablets BID during the placebo controlled phase were transitioned to 30 mg apremilast tablets BID either at Week 16 or Week 24 through to Week 260.</description>
          </group>
          <group group_id="O4">
            <title>Apremilast 20 mg/ Apremilast 30 mg</title>
            <description>Participants who were initially randomized to 20 mg apremilast tablets BID at Week 0 and transitioned to 30 mg apremilast tablets BID at either Week 16 or Week 24 through to Week 260.</description>
          </group>
          <group group_id="O5">
            <title>Apremilast 20 mg/Apremilast 20 mg</title>
            <description>Participants who were initially randomized to receive 20 mg apremilast PO BID at Week 0 and continued to receive 20 mg apremilast PO BID through to Week 260 without the transition to 30 mg apremilast PO BID.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260</title>
          <description>The Modified Stoke Ankylosing Spondylitis Spine Score is a scoring method used to determine the amount or degree of ankylosing spondylitis disease that is in the spine based on x-ray radiographs of the spine. The m-SASSS scores 0-3.
0 = No abnormality, 1 = Erosion, Sclerosis or Squaring, 2 = Syndesmophyte, 3 = Total bony Bridging at each Site. An increase in the m-SASSS indicated a worsening of AS disease.</description>
          <population>The radiograph subset analysis population included randomized participants who received at least one dose of IP and had at least a baseline radiograph available. Includes apremilast participants as treated who had a baseline and at least one post-baseline score. Missing scores were imputed using the LOCF.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="3.018"/>
                    <measurement group_id="O2" value="0.65" spread="2.453"/>
                    <measurement group_id="O3" value="0.98" spread="3.768"/>
                    <measurement group_id="O4" value="0.82" spread="2.435"/>
                    <measurement group_id="O5" value="1.12" spread="3.417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.14" spread="8.292"/>
                    <measurement group_id="O2" value="1.79" spread="6.997"/>
                    <measurement group_id="O3" value="1.92" spread="7.363"/>
                    <measurement group_id="O4" value="2.21" spread="5.959"/>
                    <measurement group_id="O5" value="3.83" spread="9.652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase</title>
        <description>A TEAE was an adverse event (AE) with a start date on or after the date of the first dose of IP and no later than 28 days after the last dose of IP for participants who discontinued early. A serious AE = results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; or constitutes an important medical event. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = symptoms causing severe pain discomfort.</description>
        <time_frame>From Week 0 to Week 24; the median duration of exposure was 23.57 weeks for the placebo arm, 23.71 weeks for the apremilast 20 mg arm and 24.00 weeks for the apremilast 30 mg arm.</time_frame>
        <population>Safety population includes all participants who were randomized and received at least one dose of IP. Includes data through Week 16 for placebo-treated and apremilast 20 mg BID treated participants who escaped early and data up to Week 24 for all other participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants initially randomized to receive placebo tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
          <group group_id="O2">
            <title>Apremilast 20 mg</title>
            <description>Participants initially randomized to 20 mg apremilast tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
          <group group_id="O3">
            <title>Apremilast 30 mg</title>
            <description>Participants initially randomized to 30 mg apremilast tablets BID in the 24-week placebo-controlled phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase</title>
          <description>A TEAE was an adverse event (AE) with a start date on or after the date of the first dose of IP and no later than 28 days after the last dose of IP for participants who discontinued early. A serious AE = results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; or constitutes an important medical event. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = symptoms causing severe pain discomfort.</description>
          <population>Safety population includes all participants who were randomized and received at least one dose of IP. Includes data through Week 16 for placebo-treated and apremilast 20 mg BID treated participants who escaped early and data up to Week 24 for all other participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Treatment Emergent Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drug-related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Serious Drug-related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE Leading to Drug Interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE Leading to Drug Withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE Leading to Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period</title>
        <description>A TEAE was an adverse event (AE) with a start date on or after the date of the first dose of IP and no later than 28 days after the last dose of IP for participants who discontinued early. A serious AE = results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; or constitutes an important medical event. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = symptoms causing severe pain discomfort.</description>
        <time_frame>Week 0 to week 260; overall mean duration of exposure to apremilast 20 mg and 30 mg BID was 160.96 weeks</time_frame>
        <population>Apremilast Subjects as Treated (AAT) were those who received at least 1 dose of apremilast at any time during the study. Participants were included in the treatment group corresponding to the apremilast dosing regimen they actually received, irrespective of the treatment group to which they were randomized or re-randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Apremilast 20 mg</title>
            <description>Participants who received 20 mg apremilast tablets BID only in the study. This also includes participants who initially received APR 20 BID and switched to APR 30 BID treatment. Only the TEAEs that occurred during the 20 mg apremilast BID dose were included.</description>
          </group>
          <group group_id="O2">
            <title>Apremilast 20/30 mg</title>
            <description>Participants who initially received 20 mg apremilast tablets BID at Week 0 who escaped to 30 mg apremilast BID. Only the TEAEs that occurred during the apremilast 30 mg BID dose were included.</description>
          </group>
          <group group_id="O3">
            <title>Apremilast 30 mg</title>
            <description>Participants initially randomized to 30 mg apremilast tablets BID at Week 0 and participants who received placebo at Week 0 who escaped to 30 mg apremilast BID. Only the TEAEs that occurred during the APR 30 mg BID dose were included.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period</title>
          <description>A TEAE was an adverse event (AE) with a start date on or after the date of the first dose of IP and no later than 28 days after the last dose of IP for participants who discontinued early. A serious AE = results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; or constitutes an important medical event. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = symptoms causing severe pain discomfort.</description>
          <population>Apremilast Subjects as Treated (AAT) were those who received at least 1 dose of apremilast at any time during the study. Participants were included in the treatment group corresponding to the apremilast dosing regimen they actually received, irrespective of the treatment group to which they were randomized or re-randomized.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Treatment Emergent Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE Leading to Drug Interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE Leading to Drug Withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE Leading to Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were reported for the placebo-controlled phase from Week 0 to Week 16 for placebo participants who entered EE at Week 16 and up to Week 24 for all other participants. AEs were reported for the apremilast (APR) exposure period from Week 0 to Week 260, irrespective of when the APR started (Week 0, 16 or 24). The median duration of treatment was 24, 163, and 216 weeks in the Apremilast 20 mg, Apremilast 20/30 mg and Apremilast 30 mg treatment groups respectively.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Weeks 0-24) Placebo-Controlled Phase</title>
          <description>Participants randomized to placebo tablets twice daily (BID) in the 24-week placebo-controlled phase.</description>
        </group>
        <group group_id="E2">
          <title>Apremilast 20 mg BID (Weeks 0-24) Placebo-Controlled Phase</title>
          <description>Participants initially randomized to 20 mg apremilast tablets (APR) BID in the 24-week placebo-controlled phase.</description>
        </group>
        <group group_id="E3">
          <title>Apremilast 30 mg BID (Weeks 0-24) Placebo-Controlled Phase</title>
          <description>Participants initially randomized to 30 mg apremilast tablets BID in the 24-week placebo-controlled phase.</description>
        </group>
        <group group_id="E4">
          <title>Apremilast 20 mg BID (APR Exposure Period)</title>
          <description>Participants who received 20 mg apremilast tablets BID only in the study. This also includes participants who initially received APR 20 BID and switched to APR 30 BID treatment.
Only the TEAEs that occurred during the 20 mg apremilast BID dose were included.</description>
        </group>
        <group group_id="E5">
          <title>Apremilast 20/30 mg BID (APR Exposure Period)</title>
          <description>Participants who initially received 20 mg apremilast tablets BID at Week 0 who escaped to 30 mg apremilast BID. Only the TEAEs that occurred during the 20 mg apremilast BID dose were included.</description>
        </group>
        <group group_id="E6">
          <title>Apremilast 30 mg BID (APR Exposure Period)</title>
          <description>Participants initially randomized to 30 mg apremilast tablets BID at Week 0 and participants who received placebo at Week 0 who escaped to 30 mg apremilast tablets BID. Only the TEAEs that occurred during the 30 mg apremilast BID dose were included.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="41" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Strabismus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Duodenogastric reflux</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Jejunal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholic liver disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cardiac function disturbance postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankylosing spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Thrombotic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Nasal turbinate hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="82" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="168" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="38" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="55" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator shall have the right to publish and/or present study data provided that the investigator shall (i) furnish the sponsor a copy of any proposed publication or presentation generally sixty (60) days in advance of the submission, (ii) delete any confidential information of the sponsor, and (iii) delay submission for generally up to ninety (90) days to permit the preparation and filing of intellectual property applications or until sponsor gives its consent in a timely manner.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anne McClain, Senior Study Manager</name_or_title>
      <organization>Celgene Corporation</organization>
      <phone>888-260-1599</phone>
      <email>ClinicalTrialDisclosure@Celgene.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

